Foley & Lardner LLP partner Anil Shankar offered insight on a recent decision which held that the federal 340B drug pricing program does not bar pharmaceutical drug manufacturers from imposing contractual conditions on contract pharmacies in the Law360 article, “DC Circ. Decision May Lead To Tighter 340B Pharma Contracts.”
Shankar explained that the decision made it clear to manufacturers that they could impose restrictions.
“It will make it easier for manufacturers to impose restrictions as long as they’re reasonable and consistent with the 340B statute,” he added.
(Subscription required)
People
Related News
06 February 2025
In the News
Vanessa Miller Assesses Panama Canal Discourse
Foley & Lardner LLP partner Vanessa Miller commented in SupplyChainBrain article, "The Fight for Control of the Panama Canal," lending important context to the recent headlines over the important waterway.
06 February 2025
In the News
Gregory Husisian Weighs in on Suspension of De Minimis Trade Exemption
Foley & Lardner LLP partner Gregory Husisian offered context on President Trump's recent trade actions on China in The Wall Street Journal article, "Why Trump Is Closing a Trade Exemption for China."
04 February 2025
In the News
Andrew Wronski on Tariff Fluidity – 'Keep on top of the issues'
Foley & Lardner LLP partner Andrew Wronski assessed the evolving shift in U.S. trade policy in the Milwaukee Business Journal article, "Trump tariffs won't disappear — so how should Wisconsin businesses prepare?"